Repository of Research and Investigative Information

Repository of Research and Investigative Information

دانشگاه علوم پزشکی و خدمات بهداشتی درمانی زنجان

Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders.

(2020) Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders. Journal of cellular physiology. pp. 4120-4134. ISSN 1097-4652 (Electronic)

Full text not available from this repository.

Official URL: https://onlinelibrary.wiley.com/doi/abs/10.1002/jc...

Abstract

Nonhematopoietic stem cells as a delivery platform of therapeutic useful genes have attracted widespread attention in recent years, owing to gained a long lifespan, easy separation, high proliferation, and high transfection capacity. Mesenchymal stem/stromal cells (MSCs) are the choice of the cells for gene and cell therapy due to high self-renewal capacity, high migration rate to the site of the tumor, and with immune suppressive and anti-inflammatory properties. Hence, it has a high potential of safety genetic modification of MSCs for antitumor gene expression and has paved the way for the clinical application of these cells to target the therapy of cancers and other diseases. The aim of gene therapy is targeted treatment of cancers and diseases through recovery, change, or enhancement cell performance to the sustained secretion of useful therapeutic proteins and induction expression of the functional gene in intended tissue. Recent developments in the vectors designing leading to the increase and durability of expression and improvement of the safety of the vectors that overcome a lot of problems, such as durability of expression and the host immune response. Nowadays, gene therapy approach is used by MSCs as a delivery vehicle in the preclinical and the clinical trials for the secretion of erythropoietin, recombinant antibodies, coagulation factors, cytokines, as well as angiogenic inhibitors in many blood disorders like anemia, hemophilia, and malignancies. In this study, we critically discuss the status of gene therapy by MSCs as a delivery vehicle for the treatment of blood disorders. Finally, the results of clinical trial studies are assessed, highlighting promising advantages of this emerging technology in the clinical setting.

Item Type: Article
Keywords: blood disorders gene delivery gene therapy hematologic malignancies mesenchymal stem cells target therapy
Subjects: QU Biochemistry. Cell Biology and Genetics > QU 300-560 Cell Biology and Genetics
WH Hemic and Lymphatic Systems > WH 120-540 Hematologic Diseases. Immunologic Factors. Blood Banks
Divisions: Education Vice-Chancellor Department > Faculty of Medicine > Department of Basic Science > Immunology Department
Page Range: pp. 4120-4134
Journal or Publication Title: Journal of cellular physiology
Abstract and Indexing: ISI, Pubmed, Scopus
Quartile : Q1
Volume: 235
Number: 5
Publisher: Wiley ,ProQuest
Identification Number: https://doi.org/10.1002/jcp.29324
ISSN: 1097-4652 (Electronic)
Depositing User: خانم فائزه مظفری
URI: http://repository.zums.ac.ir/id/eprint/6974

Actions (login required)

View Item View Item